Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CUAZ | ISIN: IE000GID8VI0 | Ticker-Symbol: 1KA
Frankfurt
20.12.24
08:06 Uhr
6,700 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GH RESEARCH PLC Chart 1 Jahr
5-Tage-Chart
GH RESEARCH PLC 5-Tage-Chart

Aktuelle News zur GH RESEARCH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.12.GH Research PLC - 6-K, Report of foreign issuer-
22.11.GH Research (NASDAQ:GHRS) Shares Down 5.1% - What's Next?2
21.11.GH Research (NASDAQ:GHRS) Trading Down 1.7% - Here's What Happened1
15.11.GH Research (NASDAQ:GHRS) Stock Price Up 0.1% - Time to Buy?2
14.11.GH Research GAAP EPS of -$0.23 beats by $0.021
14.11.GH Research PLC: GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates113Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol delivery...
► Artikel lesen
GH RESEARCH Aktie jetzt für 0€ handeln
14.11.GH Research PLC - 6-K, Report of foreign issuer-
16.09.GH Research PLC - 6-K, Report of foreign issuer1
05.09.Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials1
03.09.GH Research names new CEO amid clinical trials1
03.09.GH Research Names Velichka Villy Valcheva CEO1
03.09.GH Research PLC - 6-K, Report of foreign issuer1
03.09.GH Research PLC: GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates156Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension...
► Artikel lesen
03.09.GH Research PLC: GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer99DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
► Artikel lesen
03.05.GH Research PLC: GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates223Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase...
► Artikel lesen
29.02.GH Research PLC: GH Research Reports Full Year 2023 Financial Results and Provides Business Updates381Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum depression...
► Artikel lesen
18.01.GH Research PLC: GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression205DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1